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The recent publication in the European Heart Journal (EHJ) of 2017 cardiovascular 
disease (CVD) statistics for the 56 member countries of the European Society of 
Cardiology (ESC) is a landmark event (1).  The statistics are drawn from the Atlas 
compiled by the ESC's European Heart Agency in Brussels (2). For the first time, a 
comprehensive report has been developed for the ESC member countries with 
detailed, contemporary information about major CVD risk factors, population health 
behaviours, disease prevalence and outcomes. The Atlas also includes novel ESC 
sponsored survey data of health infrastructure and cardiovascular service provision 
provided by the national societies of ESC member countries. These data promise to 
generate interest beyond the EHJ’s cardiac readership to include an extended 
audience of patient groups, the general public, policy makers and journalists.  
 
A stand-out feature of the 2017 CVD statistics publication is its focus on health 
inequalities between ESC member countries, particularly those classified as high 
income compared with less prosperous middle income countries (Fig 1). This will 
heighten interest for policy makers by identifying regional targets for reducing the 
prevalence of CVD and improving its outcomes. For example, the Atlas data show that 
while smoking prevalence is in decline across ESC member countries, it remains a 
huge public health issue, particularly in middle income countries where >40% of men 
smoke compared with ~30% in high income countries. Hypertension too is more 
prevalent in middle income countries and it is possible to speculate that these 
unfavourable risk factor statistics contribute to the heightened prevalence of CVD. 
Indeed, just under half of the middle income ESC member countries have recorded 
an increase in disease prevalence the last 25 years unlike high income countries 
where there have been small but consistent declines. The inequalities in disease 
burden are further emphasised by a greater than three-fold excess of disability 
adjusted life years lost to ischaemic heart disease (IHD) in middle income compared 
with high income ESC member countries.  
 
The total costs of CVD are greater than for any other diagnostic group, making the 
heightened prevalence of CVD in middle income ESC member countries an economic 
issue as well as a health issue (3,4). The costs - both direct, related to disease 
management, and indirect, related to absenteeism, lost productivity and mortality - 
provide middle income countries with an unassailable economic argument to protect 
their populations against CVD. Smoking and hypertension present policy makers with 
the same targets for prevention that have contributed to the declines in CVD 
prevalence and mortality across many high income member countries. The cost 
implications of addressing these targets at a national level are inevitably more 
challenging for less prosperous member countries. However, the associations 
between GDP and the age-standardized prevalence of CVD across middle income 
countries are weak and the Russian Federation, for example, despite its considerable 
national resources, has one of the highest rates of CVD in the world. In summary, 
financial resource and health expenditure are not wholly sufficient to drive down the 
national prevalence of CVD without sound health policies that are backed up by 
effective implementation strategies. 
 
More dramatic than the changes in CVD prevalence has been the decline in CVD 
mortality that has been recorded in many ESC member countries over the last 40 
years. However, huge inequalities persist with CVD accounting for >50% of all deaths 
in many middle income countries compared with <30% in the high income countries 
of Western Europe. Declines in CVD mortality have been driven largely by reductions 
in the numbers of people presenting with myocardial infarction and stroke, with health 
gains, particularly in the more prosperous countries of Western Europe, tending to 
offset the effects of population ageing and growth (5). Whether the epidemic of obesity 
and type 2 diabetes currently rampant across ESC member countries will check this 
decline is uncertain but the omens are not good and already there are reports that 
cardiovascular mortality rates are no longer falling in younger adults (6). The Atlas 
reminds us that CVD is not only a problem for men by showing that more women, and 
a greater proportion of women, across ESC member countries are dying from CVD. 
This is largely driven by the excess of stroke and other non-IHD deaths in women, with 
IHD mortality more evenly balanced between the sexes. The huge strides that have 
been made in protection against CVD mortality have seen cancer overtaking CVD as 
the most common cause of death among men in a number of high income ESC 
member countries. The same is true for women aged <65 years for whom cancer is 
now the most common cause of premature death in countries across Europe. In these 
younger women, however, deaths from CVD remain considerably more common than 
deaths from breast cancer and, importantly, are largely preventable through risk factor 
modification of risk factors. 
 The novel ESC sponsored survey data of health infrastructure and cardiovascular 
service provision provided by the national societies of the ESC member countries add 
further interest to the 2017 CVD statistics publication. Health infrastructure, in terms 
of interventional, electrophysiological and surgical centres, for example, was better 
developed across high income compared with middle income countries. The provision 
of catheter procedures, percutaneous interventions, pacemaker insertions and bypass 
operations showed similar inequality. It could be argued that these cardiac service 
inequalities have contributed to the steeper decline in CVD mortality in high income 
compared with middle income ESC member countries but the paradox of greater 
service provision in those countries where need is manifestly less cannot be ignored. 
Resolution of the paradox is as much a question of national priority as national 
prosperity and the Atlas data make clear that inequitable  healthcare delivery is not an 
inevitable consequence of limited economic resource. It is noteworthy that in some 
middle income ESC member countries interventional procedures and device 
implantations were comparable to those in wealthier high income member countries. 
Bulgaria, for example, reported rates of coronary angiography and percutaneous 
coronary intervention that competed with the best high income countries, while Turkey 
performed more coronary bypass graft operations per million people than any other 
ESC member country. Nevertheless, across the group of middle income ESC member 
countries much work is needed to reduce population risk and improve cardiovascular 
service provision in order to close the CVD mortality gap that divides middle income 
and high income ESC member countries. The task should not be under-estimated but 
some relatively simple initiatives have the potential to deliver quick wins. For example, 
enforcement of smoking legislation is variable across middle income member 
countries and stricter control will likely yield important reductions in the incidence of 
ST elevation myocardial infarction (STEMI) (7). The benefits of reperfusion therapy for 
treatment of STEMI are also well established and the failure of some middle income 
East European member countries to offer treatment to a large proportion of their 
patients demands action (8). Measures of this sort are relatively inexpensive and can 
deliver substantial improvements in health outcomes as evidenced by the impact of 
ESC quality indicators for acute myocardial infarction which a recent study found 
applicable to large health systems with the potential to improve care and reduce 
unwarranted variation in death (9). 
The national CVD statistics curated within the Atlas are derived from a variety of 
sources including the World Health Organisation, the World Bank, the Institute for 
Health Metrics Evaluation and the Global Burden of Disease study. The ESC survey 
responses make a further contribution. Together these constitute the most credible 
available sources but, as the 2017 CVD statistics publication makes clear, the 
limitations that apply to the quality, precision and availability of the data demand 
cautious interpretation. These are country-level data that obscure regional variations 
in disease prevalence, healthcare delivery and outcomes (10). The national availability 
of interventionists and catheter laboratories documented within the Atlas, for example, 
provides a snapshot of the quality of cardiovascular care that may not be reflected in 
national outcomes. This disconnect between resources and outcomes is best 
illustrated by the United States where the national health spend towers above high 
income European countries yet the amenable mortality (the number of deaths related 
to certain diseases that could have been prevented by accessible, timely, and effective 
health care) is substantially higher (11). A more nuanced understanding of national 
differences in the quality of healthcare would require regional-, hospital- or, best of all, 
patient-level data and some focused international comparisons using sources of this 
type are now available (12,13). However, we are a long way from being able to apply 
such patient-level comparisons at scale across a broad range of nation states. 
Meanwhile, the Atlas data presented in the 2017 CVD statistics publication represent 
a major step in our understanding of the variation in cardiovascular disease 
prevalence, healthcare delivery and outcomes across the ESC member countries that 
will play an important role in underpinning the ESC’s ambitious mission “to reduce the 
burden of cardiovascular disease”.  
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Fig 1.  
 
 
 
ESC Member Countries. The World Bank defines high-income countries are those in which 
2016 gross national income per capita was US$12,000 or more. In this editorial the term 
“middle-income countries” represents a composite of upper- and lower-middle income ESC 
member countries.  
 
